CYP1A2 activity is an important determinant of clozapine dosage in schizophrenic patients

European Journal of Pharmaceutical Sciences

Volumn 20, Issue 4-5, 2003, Pages 451-457

  Doude Van Troostwijk, Lous J A E ^a   Koopmans, Richard P ^a   Vermeulen, Hans D B ^a   Guchelaar, Henk Jan ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Clozapine dose; Clozapine metabolism; CYP1A2 activity; Pharmacokinetics

Indexed keywords

COMPUTER SOFTWARE; DRUG DOSAGE; ENZYMES; METABOLISM; PATIENT TREATMENT; PHARMACOKINETICS;

CAFFEINE RATIO;

DRUG PRODUCTS;

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CAFFEINE; CLOZAPINE; CYTOCHROME P450; CYTOCHROME P450 1A2; PARAXANTHINE;

ADULT; ARTICLE; CHRONIC DRUG ADMINISTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG METABOLISM; DRUG USE; ENZYME ACTIVITY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA;

EID: 0344945498     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2003.09.010     Document Type: Article

References (23)

1. American Psychiatric Association, 1994. Diagnostic Statistical Manual, fourth ed. APA, Washington DC.
2. Baldessarini R.J., Frankenburg F.R. Clozapine, a novel antipsychotic agent. N. Eng. J. Med. 324(11):1991;746-754.
3. Bertilsson L., Carrillo J.A., Dahl M.L., Llerena A., Alm C., Bondesson U., Lindstrom L., Rodriguez de la Rubia I., Ramos S., Benitez J. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br. J. Clin. Pharmacol. 38(5):1994;471-473.
4. Carrillo J.A., Herraiz A.G., Ramos S.I., Benitez J. Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients. J. Clin. Psychopharmacol. 18(4):1998;311-316.
5. Conley R.R. Optimizing treatment with clozapine. J. Clin. Psychiatry. 59(Suppl. 3):1998;44-48.
6. Dingemans P.M.A.J., Linszen D.H., Lenior M.E., Smeets R.M.W. Component structure of the expanded brief psychiatric rating scale (BPRS-E). Psychopharmacology (Berl.). 122(3):1995;263-267.
7. Doude van Troostwijk L.J.A.E., Koopmans R.P., Guchelaar H.J. Two novel methods for the determination of CYP1A2 activity using the paraxanthine/ caffeine ratio and dietary coffee intake. Fundam. Clin. Pharmacol. 7:2003;355-362.
8. Freeman D.J., Oyewumi L.K. Will routine therapeutic drug monitoring have a place in clozapine therapy. Clin. Pharmacokinet. 32(2):1997;93-100.
9. Guitton C., Kinowski J.M., Gomeni R., Bressolle F. A kinetic model for simultaneous fit of clozapine and norclozapine concentrations in chronic schizophrenic patients during long-term treatment. Clin. Drug Invest. 16:1998;35-43.
10. Jann M.W., Grimsley S.R., Gray E.C., Chang W.H. Pharmacokinetics and pharmacodynamics of clozapine. Clin. Pharmacokinol. 24(2):1993;161-176.
11. Kalow W., Tang B.K. The use of caffeine for enzyme assays: a critical appraisal. Clin. Pharmacol. Ther. 53(5):1993;503-514.
12. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenia. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry. 45(9):1988;789-796.
13. Koch J.P., Ten Tusschler G.W., Koppe J.G., Guchelaar H.J. Validation of a high-performance liquid chromatography assay for quantification of caffeine and paraxanthine in human serum in the context of CYP1A2 phenotyping. Biomed. Chromatogr. 13:1999;309-314.
14. Kurz M., Hummer M., Kemmler G., Kurzthaler I., Saria A., Fleischhacker W.W. Long-term pharmacokinetics of clozapine. Br. J. Phychiatry. 173:1998;341-344.
15. Liu Y.Y., Doude van Troostwijk L.J.A.E., Guchelaar H.J. Simultaneous determination of clozapine, norclozapine and clozapine-N-oxide in human plasma by high-performance liquid chromatography with ultraviolet detection. Biomed. Chrom. 15:2001;280-286.
16. Miller D.D., Fleming F., Holman T.L., Perry P.J. Plasma clozapine concentrations as a predictor of clinical response: a follow-up study. J. Clin. Psychiatry. 55(Suppl. B):1994;117-121.
17. Overall J.E., Gorham D.R. The brief psychiatric rating scale. Psychol. Rep. 10:1962;799-912.
18. Overall J.E. The brief psychiatric rating scale (BPRS): recent developments in ascertainment and scaling. Psychopharmacol. Bull. 24:1988;97-98.
19. Özdemir V., Kalow W., Posner P., Collins E.J., Kennedy J.L., Tang B.K., Albers L.J., Reist C., Roy R., Walkes W., Afra P. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentration in patients with schizophrenia. J. Clin. Psychopharmacol. 21(4):2001;398-407.
20. Pirmohamed M., Park K. Mechanism of clozapine induced agranulocytosis: current status of research and implications for drug development. CNS Drugs. 7:1997;139-158.
21. Proost J.H., Meyer D.K.F. MWPharm, an intergrated software package for drug dosage regimen and therapeutic drug monitoring. Comput. Biol. Med. 22:1992;155-163.
22. Taylor D. Pharmacokinetic interactions involving clozapine. Br. J. Psychiatry. 171:1997;109-112.
23. Wetzel H., Anghelescu I., Szegedi A., Wiesner J., Weigmann H., Harter S., Hiemke C. Pharmacokinetic interactions of clozapine with selective serotonine reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. J. Clin. Psychopharmacol. 18(1):1998;2-9.